Novo Nordisk will spend £115m over a 10-year period on a new research facility in Oxford.
The Danish company’s executive vice-president and chief science officer, Mads Thomsen, described the UK’s decision to leave the European Union
Thank you for reading EG
Want to read more? Enjoy a story a day for FREE for one month.
